1. Home
  2. RNAZ vs TRNR Comparison

RNAZ vs TRNR Comparison

Compare RNAZ & TRNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNAZ
  • TRNR
  • Stock Information
  • Founded
  • RNAZ 2016
  • TRNR 2017
  • Country
  • RNAZ United States
  • TRNR United States
  • Employees
  • RNAZ N/A
  • TRNR N/A
  • Industry
  • RNAZ Biotechnology: Pharmaceutical Preparations
  • TRNR Consumer Electronics/Appliances
  • Sector
  • RNAZ Health Care
  • TRNR Technology
  • Exchange
  • RNAZ Nasdaq
  • TRNR Nasdaq
  • Market Cap
  • RNAZ 6.1M
  • TRNR 5.8M
  • IPO Year
  • RNAZ 2021
  • TRNR 2023
  • Fundamental
  • Price
  • RNAZ $11.36
  • TRNR $3.52
  • Analyst Decision
  • RNAZ Strong Buy
  • TRNR
  • Analyst Count
  • RNAZ 1
  • TRNR 0
  • Target Price
  • RNAZ $280.00
  • TRNR N/A
  • AVG Volume (30 Days)
  • RNAZ 10.7K
  • TRNR 368.2K
  • Earning Date
  • RNAZ 11-13-2025
  • TRNR 11-13-2025
  • Dividend Yield
  • RNAZ N/A
  • TRNR N/A
  • EPS Growth
  • RNAZ N/A
  • TRNR N/A
  • EPS
  • RNAZ N/A
  • TRNR N/A
  • Revenue
  • RNAZ N/A
  • TRNR $6,972,000.00
  • Revenue This Year
  • RNAZ N/A
  • TRNR $578.14
  • Revenue Next Year
  • RNAZ N/A
  • TRNR $130.65
  • P/E Ratio
  • RNAZ N/A
  • TRNR N/A
  • Revenue Growth
  • RNAZ N/A
  • TRNR 373.32
  • 52 Week Low
  • RNAZ $6.15
  • TRNR $2.81
  • 52 Week High
  • RNAZ $739.20
  • TRNR $330.00
  • Technical
  • Relative Strength Index (RSI)
  • RNAZ 56.35
  • TRNR 43.24
  • Support Level
  • RNAZ $10.67
  • TRNR $3.10
  • Resistance Level
  • RNAZ $11.45
  • TRNR $3.81
  • Average True Range (ATR)
  • RNAZ 0.61
  • TRNR 0.51
  • MACD
  • RNAZ 0.10
  • TRNR 0.07
  • Stochastic Oscillator
  • RNAZ 83.81
  • TRNR 47.08

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

About TRNR Interactive Strength Inc.

Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.

Share on Social Networks: